C4 Therapeutics
CCCC
119 hedge funds and large institutions have $1.15B invested in C4 Therapeutics in 2021 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 33 reducing their positions, and 16 closing their positions.
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
27% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 33
5% more funds holding
Funds holding: 113 → 119 (+6)
2.62% more ownership
Funds ownership: 71.19% → 73.81% (+2.6%)
25% less capital invested
Capital invested by funds: $1.54B → $1.15B (-$388M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$24.8M |
| 2 |
Millennium Management
New York
|
+$18.4M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$10.3M |
| 4 |
BlackRock
New York
|
+$9.84M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$18.1M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$11.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.94M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$7.49M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$3.88M |
CCCC Hedge Fund Activity: Q4 2021 in Review
119 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q4 2021, worth a combined $1.15B — down 25% from $1.54B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new CCCC positions and 16 closed out — a net gain of 6 holders — while 42 added to existing stakes and 33 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $24.8M. The largest seller was Jennison Associates, cutting an estimated $18.1M.
- 119 institutional investors held C4 Therapeutics (CCCC) as of Q4 2021, up from 113 in Q3 2021.
- Funds reported $1.15B of C4 Therapeutics stock for Q4 2021, down 25% quarter-over-quarter.
- 22 funds opened new C4 Therapeutics positions in Q4 2021 and 16 closed out, a net change of +6 holders.
- The largest C4 Therapeutics buyer in Q4 2021 was Morgan Stanley, an estimated $24.8M added.
- The largest C4 Therapeutics seller in Q4 2021 was Jennison Associates, an estimated $18.1M sold.
Based on aggregated 13F filings for Q4 2021.